Tvardi Therapeutics (TVRD) EBIT Margin (2013 - 2025)
Tvardi Therapeutics (TVRD) posted EBIT Margin of 169.48% for Q1 2025, up 77.17% sequentially from 742.41% in Q4 2024, and up 122003.0% YoY from N/an in Q1 2024.
Tvardi Therapeutics (TVRD) EBIT Margin (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported EBIT Margin for 13 years, with the latest figure at 169.48% in Q1 2025.
- Quarterly EBIT Margin rose 122003.0% year-over-year to 169.48% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 370.0% (up 35919.0% YoY) and the FY2024 annual result came in at 393.82%, up 18561.0% from the prior year.
- EBIT Margin grew to 169.48% in Q1 2025 per TVRD's latest filing, from 742.41% in the prior quarter.
- Over five years, EBIT Margin peaked at 5.54% in Q3 2021 and troughed at 4083.07% in Q4 2021.
- A 5-year average of 808.21% and a median of 588.28% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2021 and 2022: EBIT Margin tumbled 415325 bps in 2021, then jumped 312303 bps in 2022.
- Over 5 years, EBIT Margin stood at 4083.07% in 2021, then surged by 76 bps to 960.04% in 2022, then decreased by 13 bps to 1085.45% in 2023, then surged by 32 bps to 742.41% in 2024, then soared by 77 bps to 169.48% in 2025.
- According to Business Quant data, EBIT Margin over the past three periods registered 169.48%, 742.41%, and 222.07% for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -169.48% |
| Dec 31, 2024 | -742.41% |
| Sep 30, 2024 | -222.07% |
| Jun 30, 2024 | -724.62% |
| Mar 31, 2024 | -1,389.51% |
| Dec 31, 2023 | -1,085.45% |
| Sep 30, 2023 | -593.88% |
| Jun 30, 2023 | -466.46% |
| Mar 31, 2023 | -448.50% |
| Dec 31, 2022 | -960.04% |
| Sep 30, 2022 | -220.52% |
| Jun 30, 2022 | -19.44% |
| Mar 31, 2022 | -582.69% |
| Dec 31, 2021 | -4,083.07% |
| Sep 30, 2021 | -5.54% |
| Mar 31, 2021 | -1,217.62% |
| Dec 31, 2020 | 70.18% |
| Sep 30, 2020 | -183.68% |
| Jun 30, 2020 | -459.42% |
| Mar 31, 2020 | -370.70% |